NCT03341845View on ClinicalTrials.gov

Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC

PHASE2UnknownINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 28, 2018

Primary Completion Date

January 31, 2023

Study Completion Date

January 31, 2025

Conditions
Renal Cell Carcinoma
Interventions
DRUG

Axitinib

axitinib in combination with avelumab

DRUG

Avelumab

axitinib in combination with avelumab

Trial Locations (1)

1066CX

RECRUITING

Antoni van Leeuwenhoek, Amsterdam

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

The Netherlands Cancer Institute

OTHER

NCT03341845 - Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC | Biotech Hunter | Biotech Hunter